LEADER 04361nam 2200697 a 450 001 9910820493303321 005 20240516181431.0 010 $a9786613673718 010 $a9781118274392 010 $a1118274393 010 $a9781118274408 010 $a1118274407 010 $a9781280696756 010 $a1280696753 010 $a9781118274378 010 $a1118274377 035 $a(CKB)2670000000205429 035 $a(EBL)938848 035 $a(OCoLC)795120559 035 $a(SSID)ssj0000677315 035 $a(PQKBManifestationID)11469813 035 $a(PQKBTitleCode)TC0000677315 035 $a(PQKBWorkID)10693285 035 $a(PQKB)11117841 035 $a(MiAaPQ)EBC938848 035 $a(Au-PeEL)EBL938848 035 $a(CaPaEBR)ebr10580300 035 $a(CaONFJC)MIL367371 035 $a(OCoLC)802068199 035 $a(Perlego)999673 035 $a(EXLCZ)992670000000205429 100 $a20111025d2012 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aDrug repositioning $ebringing new life to shelved assets and existing drugs /$fedited by Michael J. Barratt, Donald E. Frail 205 $a1st ed. 210 $aHoboken $cJohn Wiley & Sons$dc2012 215 $a1 online resource (499 p.) 300 $aDescription based upon print version of record. 311 08$a9780470878279 311 08$a0470878274 320 $aIncludes bibliographical references and index. 327 $aDrug repositioning : the business case and current strategies to repurpose shelved candidates and marketed drugs / John Arrowsmith and Richard Harrison -- Opportunities and challenges associated with developing additional indications for clinical development candidates and marketed drugs / Donald Frail and Michael Barratt -- Clinical and operational considerations in repositioning marketed drugs and drug candidates / Damian O'Connell, David Sequeira, and Maria Miller -- Regulatory considerations and strategies for drug repositioning / Ken Phelps -- Computational and bioinformatic strategies for drug repositioning / Richard Mazzarella and Craig Webb -- Mining scientific and clinical databases to identify novel uses for existing drugs / Christos Andronis ... [et al.] -- Predicting the polypharmacology of drugs : identifying new uses through chemoinformatics, structural informatics and molecular modeling based approaches / Li Xie ... [et al.] -- Systematic phenotypic screening for novel synergistic combinations: a new paradigm for repositioning existing drugs / Margaret Lee -- Phenotypic in vivo screening to identify new, unpredicted indications for existing drugs and drug candidates / Michael Saporito, Christopher Lipinski, and Andrew Reaume -- Old drugs yield new discoveries : examples from the prodrug, chiral switch and site-selective deuteration strategies / Adam Morgan ... [et al.] -- Repurposing drugs for tropical diseases : case studies and open-source screening initiatives / Curtis Chong -- Drug repositioning efforts by non-profit foundations -- Business development strategies in the repositioning industry / Aris Persidis and Elizabeth Stark -- A case study in drug repositioning : Sosei / Akinori Mochizuki and Makiko Aoyama. 330 $aThe how's and why's of successful drug repositioning Drug repositioning, also known as drug reprofiling or repurposing, has become an increasingly important part of the drug development process. This book examines the business, technical, scientific, and operational challenges and opportunities that drug repositioning offers. Readers will learn how to perform the latest experimental and computational methods that support drug repositioning, and detailed case studies throughout the book demonstrate how these methods fit within the context of a comprehensive drug repositioning s 606 $aPharmaceutical industry$xEconomic aspects 606 $aDrugs$xEconomic aspects 615 0$aPharmaceutical industry$xEconomic aspects. 615 0$aDrugs$xEconomic aspects. 676 $a338.4/76151 701 $aBarratt$b Michael J$01645768 701 $aFrail$b Donald$01645769 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910820493303321 996 $aDrug repositioning$93992451 997 $aUNINA